Sanofi
Sanofi eyes phase III move for sarilumab in rheumatoid arthritis
July 13, 2011Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab
Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …
EMA widens safety review of Sanofi’s Multaq
July 12, 2011Sales and Marketing Multaq, Sanofi
European regulators are to extend their assessment of the risks associated with Sanofi’s atrial fibrillation (AF) medicine Multaq to take …
Sanofi sells dermatology unit for $425m
July 11, 2011Manufacturing and Production, Sales and Marketing Canada, Dermik, Sanofi, Valeant, dermatology
Sanofi has sold its Canadian dermatology unit Dermik for $425 million in order to concentrate on key growth areas like …
Sanofi launches Jevtana in UK
July 6, 2011Sales and Marketing Jevtana, Sanofi, prostate cancer
Sanofi has launched its promising advanced prostate cancer drug Jevtana in the UK following EMA approval in March. Jevtana (cabazitaxel) …
Sanofi to research new types of antibiotics
July 6, 2011Research and Development Antibiotics, Rib-X Pharmaceuticals, Sanofi, research and development news
Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics. The French pharma company has …
Sanofi to boost early-stage research with ‘real world’ evidence
June 23, 2011Research and Development Sanofi, patient data, pharma research
Sanofi is aiming to maximise its R&D investment by including ‘real world’ evidence in its product development strategy. The company …
Sanofi signs regenerative medicines collaboration
June 16, 2011Research and Development Audion, Sanofi, hearing loss
Sanofi has signed a research pact with Audion Therapeutics to develop regenerative medicines for hearing loss. The company’s two-year deal …
Bayer contraceptive advert breaches Code of Practice
May 27, 2011Medical Communications ABPI Code of Practice, Bayer, Multaq, Sanofi, Yasmin
Bayer Healthcare has been singled out for “particular censure” by the PMCPA, the body which regulates the ABPI Code of …
Sanofi strikes Crohn’s deal with Glenmark
May 16, 2011Research and Development Crohn’s disease, Glenmark, Sanofi
Sanofi has signed a deal with Indian drug maker Glenmark Pharmaceuticals to develop a new treatment for Crohn’s Disease. The …
Sanofi name change sees Aventis dropped
May 9, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis
Sanofi-Aventis will now just be known as Sanofi after the French pharma company’s shareholders agreed to change its name. Following …
Sanofi abandons $375m oral diabetes deal
May 9, 2011Sales and Marketing Metabolex, Sanofi, diabetes
Sanofi has terminated its $375 million deal with US biotech Metabolex to develop a novel oral anti-diabetic treatment. The French …
Sanofi seals Genzyme deal for $20 billion
February 16, 2011Research and Development, Sales and Marketing Genzyme, Sanofi
Sanofi-Aventis has finally agreed a deal to buy Genzyme for $20.1 billion after eight months of wrangling with the US …
Generics force Sanofi into standstill
February 9, 2011Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics
An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …
Diabetes success for Sanofi, disappointment for Roche
February 2, 2011Roche, Sanofi, diabetes
The contrasting fortunes of two new diabetes became clear today, with Sanofi-Aventis lixisenatide performing well, as Roche abandoned taspoglutide.Sanofi’s lixisenatide, …
Sanofi – Genzyme deal edges closer
February 1, 2011Sales and Marketing Genzyme, Lemtrada, Sanofi
Sanofi-Aventis has entered into a confidentiality agreement with Genzyme to discuss the prospects of Lemtrada, which suggests a deal could …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
